Aquestive Therapeutics is a drug manufacturers - specialty & generic business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.04 – a decrease of 5.3% over the previous week. Aquestive Therapeutics employs 142 staff and has a trailing 12-month revenue of around $57.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.04 |
|---|---|
| 52-week range | $2.24 - $5.80 |
| 50-day moving average | $2.99 |
| 200-day moving average | $3.78 |
| Wall St. target price | $9.86 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.51 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.86 from 2025-04-01
| 1 week (2025-03-26) | -8.33% |
|---|---|
| 1 month (2025-03-03) | 7.92% |
| 3 months (2025-01-03) | -20.11% |
| 6 months (2024-10-03) | -38.89% |
| 1 year (2024-04-02) | -30.92% |
|---|---|
| 2 years (2023-03-31) | 150.88% |
| 3 years (2022-04-01) | 11.28% |
| 5 years (2020-04-03) | 55.43% |
| Revenue TTM | $57.6 million |
|---|---|
| Gross profit TTM | $39.7 million |
| Return on assets TTM | -24.22% |
| Return on equity TTM | 0% |
| Profit margin | -76.68% |
| Book value | $-0.66 |
| Market Capitalization | $298.6 million |
TTM: trailing 12 months
We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $2.24 up to $5.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 2.759. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder; and Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures. The company's proprietary pipeline of complex molecule products includes AQST-108, which is in phase 2, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, which is in phase 3, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. .
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Here’s the scoop on Ark7, what it is and how it works.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
A deep dive into the highlights and limitations of Robinhood.